Trial site
San Juan Oncology Associates
Farmington, New Mexico 87401, United StatesNot linked to an institution yet
- 12running trials
- 7closed trials
The trials here
What the 19 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 26 trials
- Phase 12 trials
- Phase 41 trial
- Status
- Active, not recruiting7 trials
- Completed5 trials
- Recruiting5 trials
- Terminated1 trial
- Withdrawn1 trial
- Lead sponsor
- Hoffmann-La Roche4 trials
- Janssen Research & Development, LLC2 trials
- Cardiff Oncology1 trial
- EMD Serono Research & Development Institute, Inc.1 trial
- Genentech, Inc.1 trial
- and 10 more
Running trials
Recruiting
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
NCT07310420· Phase 1· TerSera Therapeutics LLC· Source
Contact: Jeffrey Neidhart, MD
Recruiting
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT07541170· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215· Phase 3· Hoffmann-La Roche· Source
Recruiting
Pan-tumor MRD Study
NCT06605404· Paradigm Health· Source
Contact: Jessica Barnes
Active, not recruiting
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
NCT05557591· Phase 2· Regeneron Pharmaceuticals· Source
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654· Phase 3· Gilead Sciences· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
NCT05306340· Phase 3· Genentech, Inc.· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
NCT04546009· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
NCT03395197· Phase 3· Pfizer· Source
Active, not recruiting
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
NCT03229200· Phase 4· Pharmacyclics Switzerland GmbH· Source
Active, not recruiting
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
NCT01134614· Phase 2· National Cancer Institute (NCI)· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Withdrawn
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
NCT06291415· Phase 1· Hutchmed· Source
Completed
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
NCT05593328· Phase 2· Cardiff Oncology· Source
Completed
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT04513925· Phase 3· Hoffmann-La Roche· Source
Terminated
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
NCT04032704· Phase 2· Seagen Inc.· Source
Completed
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
NCT03652064· Phase 3· Janssen Research & Development, LLC· Source
Completed
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
NCT03412565· Phase 2· Janssen Research & Development, LLC· Source
Completed
Avelumab in First-line NSCLC (JAVELIN Lung 100)
NCT02576574· Phase 3· EMD Serono Research & Development Institute, Inc.· Source
Report an error